Hong Kong Stock Connect | Genting New Era (01952) surged over 8% in early trading. Nifco's sales-driven strong growth led to a 142% increase in full-year revenue to 1.7 billion yuan.

LootboxPhobia · 2026-03-27T03:11:38+00:00

Yunding New Shine releases annual performance, with revenue increasing by 142% year-over-year, achieving a profit turnaround under non-International Financial Reporting Standards for the first time. The stock price surged over 8% in early trading. The company plans that 2026 will be a year of strategic execution, continuing to promote core drug sales and global collaborations.

LootboxPhobia

2026-03-27 03:11:38

Abstract generation in progress

Zhitong Finance APP learned that Yunding Xinyao (01952) rose more than 8% in early trading. As of the time of publication, it was up 8.36%, trading at HK$37.58, with turnover of HK$98.8559 million.

On the news front, Yunding Xinyao released its annual results. The company’s full-year revenue increased 142% year over year to RMB 1.707 billion. Under non-IFRS, it achieved a turnaround to profitability for the first time, recording a profit of RMB 187 million. Under IFRS, its loss also narrowed significantly by 71%, and operating cash flow successfully turned positive. The increase in revenue was mainly due to continued growth in sales of Naituikang in markets where it has already been commercialized.

Yunding Xinyao said that 2026 will be the “execution year” for the company’s 2030 strategy and a key year for realizing its transformation. It expects Naituikang to continue serving as the core growth engine for the company’s sales revenue in 2026. The company will advance Yijia and Weipinging’s participation in national medical insurance negotiations, while also accelerating global clinical development of its self-developed pipeline, actively seeking opportunities for global collaboration partners, and continuing to actively promote authorized in-licensing to further expand the breadth of coverage across therapeutic areas.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.